Comments on EPA Proposed Rule: Management Standards for Hazardous Waste Pharmaceuticals
Via: Regulations.gov: EPA–HQ–RCRA–2007–0932
Our organizations represent the interests of residents in long-term care facilities and other institutional practice settings, as well as the associated professionals who are committed to caring for the frailest of our citizens. We appreciate the opportunity to comment on the Environmental Protection Agency’s (EPA) proposed rule for handling hazardous waste pharmaceuticals.
The American Society of Consultant Pharmacists (ASCP) is pleased to submit comments on behalf of the undersigned organizations on the EPA’s proposed regulation on management standards for hazardous waste pharmaceuticals.
We support efforts to ensure proper handling of hazardous waste pharmaceuticals (HWP) in the long- term care (LTC) setting. Our members are committed to take all reasonable steps to ensure the safety of the LTC residents that we serve and to protect the environment.
Our organizations do have a number of concerns with the proposed rule, such as the inclusion of assisted living facilities (ALF), continuing care retirement communities (CCRC), and nursing facilities (NF) in the definition of LTC facilities, expansion of responsibilities of the pharmacy staff, and its potential impact on the viability of small healthcare entities because of the increased compliance burden.
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.